CD8highCD57+ T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer

Dobrovolskiene, Neringa; Cicėnas, Saulius; Kazlauskaitė, Nijolė; Mišeikytė-Kaubrienė, Edita; Kraśko, Jan Aleksander; Ostapenko, Valerijus; Pašukonienė, Vita; Strioga, Marius

doi:10.1016/j.lungcan.2015.08.001

Cited by 3 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though prognostic signatures to therapy have been described [11, 27, 28], phenotypic analysis of conventional markers in peripheral blood alone does not provide sufficient information about the tumor immune microenvironment and should be discouraged. Rather, paired tissue- and blood-based phenotyping should be performed, and ideally should involve conventional markers as well as novel markers to gain insight into mechanisms of therapeutic response and resistance.…”

Section: Current and Emerging Immune Monitoring Strategiesmentioning

confidence: 99%

Monitoring immune responses in the tumor microenvironment

Wargo

Reddy

Reuben

et al. 2016

Current Opinion in Immunology

100

View full text Add to dashboard Cite

Immune monitoring in the tumor microenvironment allows for important insights into immune mechanisms of response and resistance to various cancer treatments; however clinical challenges exist using current strategies. Significant questions remain regarding monitoring of archival versus fresh tissue, assessment of static versus dynamic markers, evaluation of limited tissue samples, and the translation of insights gained from immunologically “hot” tumors such as melanoma to other “cold” tumor microenvironments prevalent in other cancer types. Current and emerging immune monitoring strategies will be examined herein, and genomic-based assays complementing these techniques will also be discussed. Finally, host genomic and external environmental factors influencing anti-tumor immune responses will be considered, including the role of the gut microbiome. Though optimal immune monitoring techniques are in evolution, great promise exists in recent advances that will help guide patient selection as far as type, sequence, and combination of therapeutic regimens to enhance anti-tumor immunity and clinical responses.

show abstract

Section: Current and Emerging Immune Monitoring Strategiesmentioning

confidence: 99%

Monitoring immune responses in the tumor microenvironment

Wargo

Reddy

Reuben

et al. 2016

Current Opinion in Immunology

100

View full text Add to dashboard Cite

show abstract

CD57 in human natural killer cells and T-lymphocytes

Kared

Martelli

et al. 2016

Cancer Immunol Immunother

209

174

View full text Add to dashboard Cite

The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally differentiated 'senescent' cells with reduced proliferative capacity and altered functional properties. In this article, we review current understanding of the attributes of CD57-expressing T-cells and NK cells in both health and disease and discuss how this marker can inform researchers about their likely functions in human blood and tissues in vivo. While CD57 expression on human lymphocytes indicates an inability to proliferate, these cells also display high cytotoxic potential, and CD57(pos) NK cells exhibit both memory-like features and potent effector functions. Accordingly, frequencies of CD57-expressing cells in blood and tissues have been correlated with clinical prognosis in chronic infections or various cancers and with human aging. Functional modulation of senescent CD57(pos) T-cells and mature CD57(pos) NK cells may therefore represent innovative strategies for protection against human immunological aging and/or various chronic diseases.

show abstract